Full Text
Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain

Abstract

Authors

J. Espinosa J,L. González-Larriba P. Maroto M.J. Méndez-Vidal S. Díaz-Cerezo

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×